All In Biotech

Drug Trial Radar · NCT00412867

Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Japan Alteplase Clinical Trial Ⅱ:J-ACT Ⅱ)

Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4)

Last checked: Nov 20, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Dec 2006

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.
First posted
Dec 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA), the rate of patients with a modified Rankin Scale (mRS) score of 0-1, and the incidence of symptomatic intracranial hemorrhage (sICH), in comparison with the data reported in the current literature.

Conditions

  • Stroke

Interventions

  • AlteplaseDrug

    0.6 mg/kg of Alteplase is intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA)Time frame: within 6 hours, from 24 to 36 hours after onset
  2. Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 a 3 MonthsTime frame: 3 months after onset
  3. Number of Patients With Symptomatic Intracranial Hemorrhage (sICH) Within 36 HoursTime frame: within 36 hours after starting treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site 01

    Hokkaido, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.